Literature DB >> 11585749

Pegylation of a chlorin(e6) polymer conjugate increases tumor targeting of photosensitizer.

M R Hamblin1, J L Miller, I Rizvi, B Ortel, E V Maytin, T Hasan.   

Abstract

Photodynamic therapy is emerging as a viable modality for the treatment of many cancers. A limiting factor in its use against intracavity tumors such as disseminated ovarian cancer is insufficient selectivity of the photosensitizer for tumor compared with normal tissue. We report on an approach to improve tumor targeting by exploiting differences between cell types and by chemical modification of a photosensitizer conjugate. Attachment of polyethylene glycol (pegylation) to a polyacetylated conjugate between poly-l-lysine and chlorin(e6) increased the relative phototoxicity in vitro toward an ovarian cancer cell line (OVCAR-5) while reducing it toward a macrophage cell line (J774), compared with the nonpegylated conjugate. Surprisingly, the increased phototoxicity of the pegylated conjugate correlated with reduced oxygen consumption. Pegylation also reduced the tendency of the conjugate to aggregate and reduced the consumption of oxygen when the conjugates were illuminated in solution in serum containing medium, suggesting a switch in photochemical mechanism from type II (singlet oxygen) to type I (radicals or electron transfer). Pegylation led to more mitochondrial localization as shown by confocal fluorescence microscopy in OVCAR-5 cells, and, on illumination, produced a switch in cell death mechanism toward apoptosis not seen with J774 cells. Conjugates were injected i.p. into nude mice bearing i.p. OVCAR-5 tumors, and the pegylated conjugate gave higher amounts of photosensitizer in tumor and higher tumor:normal tissue ratios and increased the depth to which the chlorin(e6) penetrated into the peritoneal wall. Taken together, these results suggest that pegylation of a polymer-photosensitizer conjugate improves tumor-targeting and may increase the efficacy of photodynamic therapy for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Can nanotechnology potentiate photodynamic therapy?

Authors:  Ying-Ying Huang; Sulbha K Sharma; Tianhong Dai; Hoon Chung; Anastasia Yaroslavsky; Maria Garcia-Diaz; Julie Chang; Long Y Chiang; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2012-03       Impact factor: 7.848

2.  Theranostic nanoparticles for enzyme-activatable fluorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer.

Authors:  Jaehee Choi; Hyunjin Kim; Yongdoo Choi
Journal:  Quant Imaging Med Surg       Date:  2015-10

3.  Medicinal facilities to B16F10 melanoma cells for distant metastasis control with a supramolecular complex by DEAE-dextran-MMA copolymer/paclitaxel.

Authors:  Yuki Eshita; Rui-Cheng Ji; Masayasu Onishi; Takashi Kobayashi; Masaaki Mizuno; Jun Yoshida; Naoji Kubota; Yasuhiko Onishi
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

4.  Efficient microwave-assisted synthesis of amine-substituted tetrakis(pentafluorophenyl)porphyrin.

Authors:  Diana Samaroo; Clifford E Soll; Louis J Todaro; Charles M Drain
Journal:  Org Lett       Date:  2006-10-26       Impact factor: 6.005

5.  Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo.

Authors:  Li-Jun Zhang; Jun Bian; Lei-Lei Bao; Hai-Fei Chen; Yi-Jia Yan; Li Wang; Zhi-Long Chen
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-27       Impact factor: 4.553

6.  Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.

Authors:  Florencia Anatelli; Pawel Mroz; Qingde Liu; Changming Yang; Ana P Castano; Emilia Swietlik; Michael R Hamblin
Journal:  Mol Pharm       Date:  2006 Nov-Dec       Impact factor: 4.939

7.  Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.

Authors:  Imran Rizvi; Tri A Dinh; Weiping Yu; Yuchiao Chang; Margaret E Sherwood; Tayyaba Hasan
Journal:  Isr J Chem       Date:  2012-09       Impact factor: 3.333

8.  The PDT activity of free and pegylated pheophorbide a against an amelanotic melanoma transplanted in C57/BL6 mice.

Authors:  Valentina Rapozzi; Sonia Zorzet; Marina Zacchigna; Sara Drioli; Luigi E Xodo
Journal:  Invest New Drugs       Date:  2012-06-12       Impact factor: 3.850

9.  Dual-Modality Positron Emission Tomography/Optical Image-Guided Photodynamic Cancer Therapy with Chlorin e6-Containing Nanomicelles.

Authors:  Liang Cheng; Anyanee Kamkaew; Haiyan Sun; Dawei Jiang; Hector F Valdovinos; Hua Gong; Christopher G England; Shreya Goel; Todd E Barnhart; Weibo Cai
Journal:  ACS Nano       Date:  2016-07-28       Impact factor: 15.881

10.  Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate.

Authors:  Anagha Vaidya; Yongen Sun; Yi Feng; Lyska Emerson; Eun-Kee Jeong; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2008-06-27       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.